Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Regeneron Warns of Slow Praluent Uptake, While Eylea Fuels Growth

This article was originally published in Scrip

Executive Summary

Regeneron Pharmaceuticals and big pharma partner Sanofi are distributing free samples of the new cholesterol therapy Praluent (alirocumab) to patients who are awaiting insurance coverage decisions, Regeneron senior vice president of commercial Robert Terifay said during the company's Aug. 4 earnings call, while also warning that this will make it hard to assess uptake of the PCSK9 inhibitor.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts